Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Monopar Therapeutics Inc.

    NASDAQ: MNPR · Real-Time Price · USD
    37.95
    -0.06 (-0.17%)
    At close: Jun 06, 2025, 3:59 PM
    37.11
    -2.21%
    After-hours: Jun 06, 2025, 04:04 PM EDT

    Monopar Therapeutics Statistics

    Share Statistics

    Monopar Therapeutics has 6.12M shares outstanding. The number of shares has increased by -65.1% in one year.

    Shares Outstanding

    n/a
    		 6.12M

    Shares Change (YoY)

    n/a
    		 -65.1%

    Shares Change (QoQ)

    n/a
    		 0.43%

    Owned by Institutions (%)

    n/a
    		 6.8%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1,034

    FTD / Avg. Volume

    n/a
    		 4.28%

    Short Selling Information

    The latest short interest is 38.03K, so 0.62% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 38.03K

    Short % of Shares Out

    n/a
    		 0.62%

    Short % of Float

    n/a
    		 1.97%

    Short Ratio (days to cover)

    n/a
    		 2

    Valuation Ratios

    The PE ratio is -0.05 and the forward PE ratio is -10.24. Monopar Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.05

    Forward PE

    n/a
    		 -10.24

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 2.3

    PB Ratio

    n/a
    		 0.02

    P/FCF Ratio

    n/a
    		 -130.2

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Monopar Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.01, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 0.01

    Quick Ratio

    n/a
    		 0.01

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,113,315,642.86

    Employee Count

    n/a
    		 14

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 722.8% in the last 52 weeks. The beta is 1.01, so Monopar Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.01

    52-Week Price Change

    n/a
    		 722.8%

    50-Day Moving Average

    n/a
    		 37.28

    200-Day Moving Average

    n/a
    		 25.24

    Relative Strength Index (RSI)

    n/a
    		 54.5

    Average Volume (20 Days)

    n/a
    		 24,133

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -16.16B

    Net Income

    n/a
    		 -15.59B

    EBITDA

    n/a
    		 -15.59M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -411.23
    Full Income Statement

    Balance Sheet

    The company has 45.82M in cash and 0 in debt, giving a net cash position of 45.82M.

    Cash & Cash Equivalents

    n/a
    		 45.82M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -75.79B

    Total Assets

    n/a
    		 55.09B

    Working Capital

    n/a
    		 53.58B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -6.4M and capital expenditures 0, giving a free cash flow of -6.4M.

    Operating Cash Flow

    n/a
    		 -6.4M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -6.4M

    FCF Per Share

    n/a
    		 -0.17
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    MNPR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for MNPR is $50, which is 30.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $50

    Price Target Difference

    n/a
    		 30.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Aug 13, 2024. It was a backward split with a ratio of 1:5.

    Last Split Date

    n/a
    		 Aug 13, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:5

    Scores

    Altman Z-Score

    n/a
    		 -0.94

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist